Opening New Frontiers By Advancing The Promise of PI Signaling Pathways
Robert Abraham, Ph.D.
Select a team to find out more
Robert Abraham, Ph.D.
Senior Vice President, Group Head of Oncology Research and Development, Pfizer, Inc.
As Senior Vice President and Group Head of the Oncology R&D Group at Pfizer Worldwide Research and Development (WRD), Dr. Robert “Bob” Abraham is a standing member of the WRD leadership team, and founder of the Pfizer WRD Postdoc Training Program. Prior to these roles, Bob served in Wyeth Research as Vice President of Oncology Research, one of the five therapeutic areas in Wyeth Discovery Research.
Before he joined Wyeth, Bob held faculty positions at various research and academic facilities. He was named a professor at the Sanford-Burnham Institute for Medical Research (SBIMR), and served as a founding director of the Signal Transduction Research Program. He was also named Director of the SBIMR Cancer Research Center, and successfully led the facility to the renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the U.S.
Bob remains an adjunct professor at SBIMR, and an adjunct professor of pharmacology at the University of California – San Diego. He served as a professor in the Department of Pharmacology and Cancer Biology at the Duke University Medical Center from 1998 to 2001, where he was also the first recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology. Bob also served as Associate Director of Translational Research in the Duke Comprehensive Cancer Center. At the Mayo Clinic in Rochester, Minn. Bob rose through the ranks to become a professor in the Department of Immunology and the Department of Pharmacology. He also served as Director of Basic Sciences in the Mayo Comprehensive Cancer Center.
Bob’s major research interests included characterization and functional analysis of the mammalian Target of Rapamycin signaling pathway, cancer metabolism, signal transduction mechanisms in T-lymphocytes, and molecular mechanisms underlying cellular responses to DNA damage. He also holds several patents related to anticancer drug development.
Bob earned a B.S. in biology from Bucknell University in 1974, and subsequently received a Ph.D. in pharmacology from the University of Pittsburgh. In 1981, Bob was a Postdoctoral Fellow in pharmacology and immunology at the Mayo Clinic. Bob has authored more than 210 scientific publications. He has also served on and chaired grant review panels at the National Institutes of Health and served as a reviewer for many top scientific journals, including Nature, Science, and Cell. Bob has received several awards for his scientific contributions, including the Legacy Laureate Award as an outstanding alumnus of the University of Pittsburgh.